1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Correction: BBS-Bioactive Bone Substitutes Oyj – Insider information: CEO Juliusz Rakowski has terminated the CEO agreement

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | December 18, 2024 at 14:00:00 EET

CORRECTION: "Changes in the Management team" in the title has been corrected to "Insider information". Below is the corrected release in full:

BBS-Bioactive Bone Substitutes Oyj – Insider information: CEO Juliusz Rakowski has terminated the CEO agreement

CEO Juliusz Rakowski has terminated the CEO agreement between the Company and the CEO. Rakowski will continue in his position until February 28, 2025.

CEO Juliusz Rakowski: "I am grateful for the opportunity to be part of this journey and to lead talented people across various departments in the organization. I thank the Board, shareholders, partners, and the Company's dedicated employees for their cooperation."

For more information, please contact:
Pekka Jalovaara, the Chairman of the Board
+358 50 5529 275
pekka.jalovaara@bbs-artebone.fi

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Oyj – Insider information: CEO Juliusz Rakowski has terminated the CEO agreement

Datum 2024-12-18, kl 13:00
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Oyj – Insider information: CEO Juliusz Rakowski has terminated the CEO agreement